Literature DB >> 19717980

Survivin as a global target of intrinsic tumor suppression networks.

Minakshi Guha1, Dario C Altieri.   

Abstract

Despite the constant exposure to genomic insults that may lead to malignancy, cancer is surprisingly a relatively rare occurrence, and this is largely credited to an elaborate network of endogenous tumor suppression. Many effectors of tumor suppression have been identified, and their functions when activated in damaged cells have in large part been elucidated. What is less clear is whether there are common target gene(s) of tumor suppression, whose expression must be ablated in order to block transformation and preserve cellular homeostasis. Fresh experimental evidence suggests that silencing of the mitotic regulator and cell death inhibitor, survivin, is a universal requirement for successful tumor suppression in humans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19717980      PMCID: PMC2819076          DOI: 10.4161/cc.8.17.9457

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  27 in total

1.  Growth factor-dependent regulation of survivin by c-myc in human breast cancer.

Authors:  Niamh Cosgrave; Arnold D K Hill; Leonie S Young
Journal:  J Mol Endocrinol       Date:  2006-12       Impact factor: 5.098

2.  Transcriptional activation of survivin through the NF-kappaB pathway by human T-cell leukemia virus type I tax.

Authors:  Hirochika Kawakami; Mariko Tomita; Takehiro Matsuda; Takao Ohta; Yuetsu Tanaka; Masahiro Fujii; Masahiko Hatano; Takeshi Tokuhisa; Naoki Mori
Journal:  Int J Cancer       Date:  2005-07-20       Impact factor: 7.396

3.  The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression.

Authors:  F Li; D C Altieri
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  Colonic crypt changes during adenoma development in familial adenomatous polyposis: immunohistochemical evidence for expansion of the crypt base cell population.

Authors:  Bruce M Boman; Rhonda Walters; Jeremy Z Fields; Albert J Kovatich; Tao Zhang; Gerald A Isenberg; Scott D Goldstein; Juan P Palazzo
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

5.  Mitosis-independent survivin gene expression in vivo and regulation by p53.

Authors:  Fang Xia; Dario C Altieri
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

6.  The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity.

Authors:  Jörg Weiske; Kai Frederik Albring; Otmar Huber
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-10       Impact factor: 11.205

7.  Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity.

Authors:  Khandaker Siddiquee; Shumin Zhang; Wayne C Guida; Michelle A Blaskovich; Benjamin Greedy; Harshani R Lawrence; M L Richard Yip; Richard Jove; Mark M McLaughlin; Nicholas J Lawrence; Said M Sebti; James Turkson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-26       Impact factor: 11.205

8.  Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma.

Authors:  Ilya V Ulasov; Zeng B Zhu; Matthew A Tyler; Yu Han; Angel A Rivera; Andrey Khramtsov; David T Curiel; Maciej S Lesniak
Journal:  Hum Gene Ther       Date:  2007-07       Impact factor: 5.695

Review 9.  AKT/PKB signaling: navigating downstream.

Authors:  Brendan D Manning; Lewis C Cantley
Journal:  Cell       Date:  2007-06-29       Impact factor: 41.582

10.  Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential.

Authors:  S Semba; F Trapasso; M Fabbri; K A McCorkell; S Volinia; T Druck; D Iliopoulos; Y Pekarsky; H Ishii; P N Garrison; L D Barnes; C M Croce; K Huebner
Journal:  Oncogene       Date:  2006-05-11       Impact factor: 8.756

View more
  53 in total

1.  The involvement of survivin in insulin-like growth factor 1-induced epithelial-mesenchymal transition in gastric cancer.

Authors:  Chengjun Li; Jinbao Li; Dawei Wu; Gang Han
Journal:  Tumour Biol       Date:  2015-08-14

2.  Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis.

Authors:  Markus Kaller; Sven-Thorsten Liffers; Silke Oeljeklaus; Katja Kuhlmann; Simone Röh; Reinhard Hoffmann; Bettina Warscheid; Heiko Hermeking
Journal:  Mol Cell Proteomics       Date:  2011-05-12       Impact factor: 5.911

3.  Functional genomics identify Birc5/survivin as a candidate gene involved in the chronotoxicity of cyclin-dependent kinase inhibitors.

Authors:  Sandrine Siffroi-Fernandez; Sandrine Dulong; Xiao-Mei Li; Elisabeth Filipski; Aline Gréchez-Cassiau; Brigitta Peteri-Brünback; Laurent Meijer; Francis Lévi; Michèle Teboul; Franck Delaunay
Journal:  Cell Cycle       Date:  2014-01-21       Impact factor: 4.534

4.  TGF-β Regulates Survivin to Affect Cell Cycle and the Expression of EGFR and MMP9 in Glioblastoma.

Authors:  Wenliang Chen; Xiao Zhong; Yi Wei; Yun Liu; Quan Yi; Genshui Zhang; Lishan He; Fajiang Chen; Yingping Liu; Jiandong Luo
Journal:  Mol Neurobiol       Date:  2015-02-17       Impact factor: 5.590

5.  Activation of CXCL12/CXCR4 renders colorectal cancer cells less sensitive to radiotherapy via up-regulating the expression of survivin.

Authors:  Dawei Wang; Chengbin Jiao; Yanli Zhu; Deshen Liang; Ming Zao; Xiangyu Meng; Jianwei Gao; Yunlong He; Weixin Liu; Jie Hou; Zhaohua Zhong; Zhuoxin Cheng
Journal:  Exp Biol Med (Maywood)       Date:  2016-10-23

6.  Role of hypoxia-inducible factors in the dexrazoxane-mediated protection of cardiomyocytes from doxorubicin-induced toxicity.

Authors:  R D Spagnuolo; S Recalcati; L Tacchini; G Cairo
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

7.  Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells.

Authors:  Aki Iwai; Dimitra Bourboulia; Mehdi Mollapour; Sandra Jensen-Taubman; Sunmin Lee; Alison C Donnelly; Soichiro Yoshida; Naoto Miyajima; Shinji Tsutsumi; Armine K Smith; David Sun; Xiaolin Wu; Brian S Blagg; Jane B Trepel; William G Stetler-Stevenson; Len Neckers
Journal:  Cell Cycle       Date:  2012-08-30       Impact factor: 4.534

8.  Annonaceous acetogenins reverses drug resistance of human hepatocellular carcinoma BEL-7402/5-FU and HepG2/ADM cell lines.

Authors:  Jun-Qiang Qian; Pei Sun; Zhan-Yu Pan; Zhi-Zhong Fang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

9.  Overexpression of survivin initiates hematologic malignancies in vivo.

Authors:  S Small; G Keerthivasan; Z Huang; S Gurbuxani; J D Crispino
Journal:  Leukemia       Date:  2010-09-30       Impact factor: 11.528

10.  Increased survivin expression contributes to apoptosis-resistance in IPF fibroblasts.

Authors:  Thomas H Sisson; Toby M Maher; Iyabode O Ajayi; Jessie E King; Peter D R Higgins; Adam J Booth; Rommel L Sagana; Steven K Huang; Eric S White; Bethany B Moore; Jeffrey C Horowitz
Journal:  Adv Biosci Biotechnol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.